Hosted on MSN9mon
Biodexa shares rally 126% on rapamycin licensing dealShares of Biodexa (NASDAQ:BDRX) soared 126% in early trading Friday after the company announced it had entered into an exclusive worldwide license to develop and commercialize eRapa, also known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback